ANTITUMOR AND IMMUNE-BIOLOGICAL ACTIVITY OF A NEW METRONOMIC CHEMOTHERAPY WITH FRACTIONED CISPLATIN AND ORAL ETOPOSIDE COMBINED WITH BEVACIZUMAB (MPEBEV) FOLLOWED BY ERLOTINIB MAINTENANCE IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS

被引：0
|
作者：
Correale, Pierpaolo [1 ]
Martellucci, Ignazio [2 ]
Pastina, Pierpaolo [3 ]
Botta, Ciri-No [4 ]
Martino, Elodia [3 ]
Mazza, Daniela [3 ]
Tagliafer-Ri, Pierosandro [4 ]
Pirtoli, Luigi [3 ]
Caraglia, Michele [5 ]
机构：
[1] Siena Univ Hosp, Translat Immunooncol Ctr, Radiotherapy Unit, Siena, Italy
[2] Siena Univ Hosp, Siena, Italy
[3] Univ Siena, Unit Radiotherapy, I-53100 Siena, Italy
[4] Magna Graecia Univ Catanzaro, Med Oncol Unit, Catanzaro, Italy
[5] Univ Naples 2, Naples, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Metronomic Chemotherapy; Bevacizumab; immunebiological actvity; erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-028
引用
收藏
页码：S607 / S608
页数：2
相关论文
共 50 条
  • [21] A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients.
    Horn, Leora
    Li, Chung-I
    Pao, William
    Keedy, Vicki Leigh
    Johnson, David H.
    Carbone, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] ANTITUMOR ACTIVITY OF BEVACIZUMAB COMBINED WITH ERLOTINIB IN T790M RESISTANCE MUTATION POSITIVE NON-SMALL CELL LUNG CANCER XENOGRAFT MODELS
    Furugaki, K.
    Yamamoto, K.
    Moriya, Y.
    Suda, K.
    Mizuuchi, H.
    Mitsudomi, T.
    Harada, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [23] PHASE II STUDY OF METRONOMIC CHEMOTHERAPY (MC) WITH BEVACIZUMAB (B) IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NS-NSCLC)
    Robert, Francisco
    Grant, Stefan C.
    Jerome, Mary
    Miley, Debi
    Reddy, Vishnu
    Cantor, Alan
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1186 - S1187
  • [24] Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study
    Roberto Petrioli
    Edoardo Francini
    Anna Ida Fiaschi
    Letizia Laera
    Luca Luzzi
    Piero Paladini
    Claudia Ghiribelli
    Luca Voltolini
    Vincenzo Bianco
    Giandomenico Roviello
    Medical Oncology, 2015, 32
  • [25] Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study
    Petrioli, Roberto
    Francini, Edoardo
    Fiaschi, Anna Ida
    Laera, Letizia
    Luzzi, Luca
    Paladini, Piero
    Ghiribelli, Claudia
    Voltolini, Luca
    Bianco, Vincenzo
    Roviello, Giandomenico
    MEDICAL ONCOLOGY, 2015, 32 (04)
  • [26] Sub-analyses of responders of a phase III trial of erlotinib combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Reck, Martin
    Klughammer, Barbara
    Montavon, Pierre
    Ward, Carol
    De Rosa, Flavio
    Brennscheidt, Ulrich
    Gatzemeier, Ulrich
    ANNALS OF ONCOLOGY, 2004, 15 : 169 - 170
  • [27] Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer
    Lee, DH
    Han, JY
    Cho, KH
    Pyo, HR
    Kim, HY
    Yoon, SJ
    Lee, JS
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (04): : 1037 - 1044
  • [28] Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gatzemeier, U
    Pluzanska, A
    Szczesna, A
    Kaukel, E
    Roubec, J
    Brennscheidt, U
    De Rosa, F
    Mueller, B
    Von Pawel, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 619S - 619S
  • [29] Phase II study of induction chemotherapy followed by radiotherapy combined with daily cisplatin in stage III inoperable non-small cell lung cancer (NSCLC).
    Scolaro, T
    Ardizzoni, A
    Giudici, S
    Grossi, F
    Cosso, M
    Pennucci, MC
    Bacigalupo, A
    Rosso, R
    Vitale, V
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (02): : 313 - 313
  • [30] Phase II study of simultaneous radiochemotherapy (RCT) with cisplatin/etoposide followed by consolidation chemotherapy (CT) with platin/gemcitabine for unresectable non-small cell lung cancer (NSCLC)
    Fink, T. H.
    Melzner, W.
    Strnad, V.
    Sauer, R.
    Albrecht, C.
    Birkenhake, S.
    Ficker, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345